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Aim: The role of high mobility group box protein 1 (HMGB1) in non-small cell lung cancer
(NSCLC) is unknown. We investigated the contributions of HMGB1 in NSCLC, and analyze the
correlation between HMGB1 and clinicopathologic outcomes.
Patients and methods: A total of 145 patients with diagnosed NSCLC, and 77 patients with
diagnosed chronic obstructive pulmonary disease (COPD) (51 chronic bronchitis and 26 obstruc-
tive pulmonary emphysema), and 49 healthy volunteers were enrolled from January 2005
through July 2008. HMGB1 levels were analyzed by Western blot analysis.
Results: The mean value of serum HMGB1 levels in 145 patients with lung cancer was
76.1  37.0 ng/ml and was significantly higher than those in 77 COPD patients
(39.8 10.8 ng/ml), and 49 healthy control (7.7 6.1 ng/ml, p< 0.0001, respectively); The
serum HMGB1 levels were 30.2  5.9 ng/ml, 60.9  22.5 ng/ml, 99.0  23.1 ng/ml and
133.4 18.9 ng/ml in patients with NSCLC of TNM stage I, II, III, and IV. There were significant
differences among four groups (p< 0.0001). Moreover, the significant positive correlation
between the levels of serum HMGB1 and the size of tumor (rZ 0.799, p< 0.001); The serum
HMGB1 levels were 57.2  28.8 ng/ml in patients with NSCLC before operation, and
26.5 14.7 ng/ml one month after operation (p< 0.0001).
Conclusions: Our study suggests that HMGB1 may be a useful clinical marker for evaluating the
NSCLC progression and is of potential prognostic value.
ª 2009 Elsevier Ltd. All rights reserved.1 82169558.
6@163.com (G.-H. Shang).
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High mobility group box protein 1 (HMGB1) is a non-histone,
chromatin-binding nuclear protein which has a highly
conserved sequenceamongvarious specieswithmurineHMGB1
differing from the human form by only two amino acids, and
structurally organized into two DNA-blinding domains (termed
A and B box) and a negatively charged C-terminal tail.1,2
HMGB1-deficient mice die within a few hours of birth, demon-
strating the crucial role of this protein in cellular function.3
HMGB1 appears to have two distinct functions in cellular
systems. Intranuclearly, it binds without sequence speci-
ficity to the minor groove of DNA, which stabilizes nucleo-
some formation, regulates gene transcription and the
activity of steroid hormone receptors.4 Extracellular HMGB1
has been demonstrated to be involved in inflammatory
processes, the mediation of neurite outgrowth, smooth
muscle cell chemotaxia, mesoangioblast migration and
proliferation, and tumor growth and metastasis.4e7 Intra-
nuclear HMGB1 reaches the extracellular environment by
passive release from necrotic cells and active secretion from
cells of innate immune system.8,9 The preliminary study
showed that the tumor cell death induced by a variety of
agents such as cancer chemotherapeutic agents, oncolytic
viruses, ultraviolet or gamma irradiation, and cytolytic Tand
NK cells indicated classic markers of apoptosis that were
associated with significant HMGB1 release.10,11Extracellular
HMGB1 induces cancer cell growth, mobility, invasion, and
metastasis via binding to specific membrane receptors
including the receptor for advanced glycation end products
(RAGE), and blockade of the RAGE-HMGB1 interaction
suppresses tumor growth and metastasis.12e14 Moreover,
constant release of HMGB1 as a proinflammatory cytokine
from necrotic tumor cells would create a microenvironment
similar to chronic inflammations, this condition known to
contribute to the development of epithelial malignancies.15
Lung cancer is the leading cause of malignancy-related
death worldwide, with a poor prognosis. The reason of the
extraordinarily aggressive biological behavior of this tumor
is unknown. The clinical behavior of lung cancer is largely
dependent on its stage, and the 5-year survival rate for all
stages combined is only 16%, but the survival rate is 49% for
early stages when the lesions is localized and amenable to
curative surgical resection. Therefore, the search for an
early biological marker of tumor invasiveness in lung cancer
is of clinical importance. Overexpression of RAGE in lung
epithelium suggested that HMGB1 may be play a pivotal role
in the development of lung cancer.16 Moreover, the levels
of HMGB1 expression are strongly correlated with tumor
metastasis,17 but, until now, the serum levels of HMGB1
have not been evaluated in lung cancer. In this study, we
measured the serum levels of HMGB1 by Western blot
analysis and assessed interrelationship between HMGB1 and
clinic pathological parameters in patients with lung cancer.
Materials and methods
Patients
A total of 145 patients with diagnosed non-small cell lung
cancer (NSCLC), and 77 patients with diagnosed chronicobstructive pulmonary disease (COPD) (51 chronic bron-
chitis and 26 obstructive pulmonary emphysema), and 49
healthy volunteers were enrolled from January 2005
through July 2008 at Department of Respiratory Medicine
and Chest Surgery, Qilu Hospital, Shandong University. The
volunteers and patients who gave written informed consent
entered this study, which was approved by the investigation
and ethics committee of hospital according to the stan-
dards of the Declaration of Helsinki. All of patients were
diagnosed by various methods including sputum cytology,
fine-needle aspiration, bronchoscopy, or thoracentesis. The
stage of lung cancer was based on the international staging
system,18 and the staging procedure included a clinical
examination; standard chest radiography; CT scans of the
chest, abdomen, and brain; bronchoscopy; liver ultraso-
nography; and bone scanning; and positron emission
tomography. The tumor size was measured by CT scans.
Inclusion criteria: male or female NSCLC, COPD and control
subjects, aged 40e75 years; a baseline FEV1< 80% of pre-
dicted normal and a baseline FEV1/FVC ratio< 70% for the
COPD patients; a baseline FEV1> 80% of predicted normal
and a baseline FEV1/FVC ratio> 70% for the NSCLC
patients; a signed and dated written informed consent is
obtained prior to participation. For the control subjects,
they are free from significant disease as determined by
history, physical examination and screening investigates.
Exclusion criteria: prior tumor illness (diagnosis made from
history, physical examination and screening investigates),
prior NSCLC therapy, trauma/fracture, inflammatory
systemic disease or infection, rheumatologic disease,
stroke, vascular or other internal medical conditions.
Anyone had not taken the medication that may influence
the level of HMGB1 (eg, nonsteroidal anti-inflammatory
drugs, oral or local corticosteroids and anticytokine
therapy) within one month. The volunteers and patients
were both age- and sex-matched. 79 patients were per-
formed operation, and serum HMGB1 levels of theses
patients were measured before operation and one month
after operation. The clinic pathologic characteristics of
patients were in Table 1.HMGB1 measurements
All blood samples were collected in non-heparinized tubes
and allowed to clot at room temperature for half an hour,
then centrifuged for 15 min, and serum collected for
storage at 80 C in microfuge tubes until assayed. HMGB1
levels were measured by Western blot analysis with refer-
ence to standard curves of purified HMGB1 as previously
described.19 In brief; sera samples were thawed on dry ice.
Serum samples (100e200 ml) was ultrafiltered with Micro-
con YM-100 filters (Millpore, Billerica, MA, USA). Filtrate
was transferred to a new clean Eppendorf tube,
2 Laemmli sample buffer (Bio-Rad, Laemmli Sample
Buffer, Hercules, CA, USA) was made with b-mercaptoe-
thanol (Bio-Rad) according to manufacture’s instructions,
heated at 95 C for five minutes and spun down at
10,000 rpm for 5 min in tabletop microfuge. Samples were
subjected to electrophoresis through 10e20% TriseHCI
acrylamide gels (Bio-Rad) and transferred to pre-activated
polyvinyline fluoride (PVDF) membrane (Bio-Rad, Hercules,
Table 1 Baseline characteristics of the lung cancer patients.
Variables Lung cancer COPD Control P-value
Subjects, No 145 77 49
Age (y)a 59.2 (8.7) 60.3 (7.0) 60.6 (7.4) 0.44
Male/femaleb 105 (72)/40 (28) 59 (77)/18 (23) 34 (69)/15 (31) 0.65
Smoker 100 (69) 53 (69) 19 (39) <0.01
FVC (% pred) 100 10 77 17 <0.01c
FEV1 (% pred) 94 8 49 15 <0.01c
FEV1/FVC 78 5 51 10 <0.01c
Cell typeb
Squamous 70 (48)
Adenocarcinoma 65 (45)
Large cell 8 (6)
BAC 2 (1)
TNM stage (I/II/III/IV)b 22 (15)/62 (43)/44 (30)/17 (12)
Distance metastasisb
Non-metastasis 128(88)
Metastasis 17(12)
a Mean (SD).
b Numbers (%).
c Lung cancer versus COPD; COPD, chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV1, forced expiratory volume
at 1st second; BAC, bronchioloalveolar carcinoma.
Figure 1 Serum HMGB1 levels in patients with lung cancer.
*,#Significantly lower versus lung cancer (p< 0.0001,
respectively).
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anol, rinsed and equilibrated in Tris/Glycine/20% Methanol
transfer buffer (Bio-Rad). After transfer, the membrane
was rinsed for 5 min with wash buffer and 0.02% Tween 20
(Bio-Rad). Wash buffer was removed and incubated with 5%
blocking buffer (Bio-Rad, Blotting grade blocker non-fat dry
milk) for 1 h at room temperature. The membrane was
probed overnight at 4 C with purified IgG from anti-HMGB1
antiserum (2 ml/ml in 1% non-fat dry milk in wash buffer).
PVDF membrane was washed 4 times at 15 min intervals in
wash buffer and then incubated with peroxides conjugated
anti-rabbit secondary antibody (Amersham Biosciences,
Piscataway, NJ, USA) at dilution 1:5000 for 1 h. The
membrane was washed three times at 15 min internals in
wash buffer and 5 min with phosphate-buffered saline.
PVDF membrane was developed using ECL Western blotting
detection reagents (Amersham Biosciences, Piscataway,
NJ, USA). Equal volumes of ECL A and B were added to the
PVDF membrane and incubated for 1 min. PVDF membrane
was then exposed to Hyperfilm (fisher Scientific, Pitts-
burgh, PA). Autoradiography films were scanned, and
densitometry analyses were performed using Quantity One
software (Bio-Rad) and Microsoft Excel. The levels of
HMGB1 were determined by reference to standard curves
generated with purified HMGB1.
Statistical analysis
One-way analysis of variance (ANOVA) with post-hoc Bon-
ferroni adjustment for pairwise comparison was used to
compare the means of HMGB1 among groups. Pearson
correlation analysis was performed to assess the correla-
tions between HMGB1 and the continuous variables. All
statistical analyses were carried out with STATA version 9.2
(Stata Corporation, College Station, TX, USA). All reportedprobabilities (p-value) were two-sided, and less than 0.05
was considered statistically significant.
Results
Serum HMGB1 levels in patients with lung cancer
The mean value of serum HMGB1 levels in 145 patients with
lung cancer was 76.1 37.0 ng/ml and was significantly
higher than those in 77 COPD patients (39.8 10.8 ng/ml),
and 49 healthy control (7.7 6.1 ng/ml, p< 0.0001,
respectively, Fig. 1) and the difference was also found
between COPD patients and control (p< 0.001).
Figure 3 Correlation of serum HMGB1 levels with tumor size
in patients with lung cancer. Strong correlation between the
serum HMGB1 levels and tumor size, rZ 0.799, p< 0.001.
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with different tumor stage of NSCLC
The tumor stage was defined by the international staging
system (TNM stage) for NSCLC to evaluate whether HMGB1
was associated with lung cancer metastases to lymph
nodes, distal organs, and tumor characteristics. The serum
HMGB1 levels were 30.2 5.9 ng/ml, 60.9 22.5 ng/ml,
99.0 23.1 ng/ml and 133.4 18.9 ng/ml in patients with
NSCLC of TNM stage I, II, III, and IV. There were significant
differences among four groups (p< 0.0001) and between
two groups (Fig. 2). Moreover, the serum HMGB1 levels
were notably increased in patients with distant metastasis
(133.4 18.9 ng/ml) than none distant metastasis
(68.46 31.9 ng/ml, p< 0.0001).
Comparison the serum HMGB1 levels in patients
with different size of lung cancer
We divided the tumors into three groups by their maximum
size: <4 cm and 4 cm to compare the serum HMGB1 levels
in patients with different size of lung cancer. For the
patients with <4 cm and 4 cm lung tumor lesions, the
serum HMGB1 levels were 52.3 23.9 ng/ml and
105.3 28.3 ng/ml (p< 0.0001), and the significant posi-
tive correlation between the levels of serum HMGB1 and
the size of tumor (rZ 0.799, p< 0.001; Fig. 3).
The serum HMGB1 levels in patients with lung
cancer before operation and one month after
operation
To determine whether the serum HMGB1 levels of pre-
operation patients were different from post-operation, we
measured the serum HMGB1 levels of the same operated
patients before operation and one month after operation.
The serum HMGB1 levels were 57.2 28.8 ng/ml in patients
with NSCLC before operation, and 26.5 14.7 ng/ml one
month after operation (p< 0.0001) (Fig. 4).Figure 2 Serum levels of HMGB1 in patients with tumors of
different stage. Value among four groups was significantly
different (p< 0.0001); *versus stage I group, p< 0.001; #versus
stage II group, p< 0.001; $versus stage III group, p< 0.001.Discussion
Cancer development is associated with the HMGB1 which
modulates the transcriptional activity in the nucleus, and
also present in the cytoplasm and outside the cell in certain
conditions.6e9 In cancer cells, HMGB1 supports cell trans-
formation, growth and cellular resistance.12e14,17 In the
current study, we have first demonstrated that serum
HMGB1 levels were significantly increased in patients with
lung cancer than those in patients with COPD and controls.
Although the lung surgery has effect on the HMGB levels,
the serum HMGB1 levels after surgery revealed a significant
decrement than preoperative levels (P< 0.0001). These
results suggest that HMGB1 may play an important role in
the development of lung cancer. Several factors may
contribute to elevation in serum HMGB1 levels in the
patients with lung cancer. One is that lung cancer cells
produce and secrete HMGB1. Lim’s research showed that
human lung adenocarcinoma cell line A 549 release HMGB1,
and ethyl pyruvate, a simple aliphatic ester contributes to
its anti-inflammatory action and suppresses tumor devel-
opment through inhibiting cancer cells HMGB1 release.20 On
the other hand; it was well known that HMGB1 can be
passively released by necrotic and ischemic cells.10,11 InFigure 4 Serum levels of HMGB1 in patients with lung cancer
before operation and one month after operation. *Significantly
lower versus pre-operation (p< 0.0001).
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in response of oxygen and glucose deletion because tumor
cells proliferation may outpace the rate of angiogenesis,
resulting in tissue severe ischemic hypoxia.21 Oxygen and
glucose deletion induced necrotic cell death is thought to
contribute to tumor growth and aggressiveness through
a tumor promoting cytokine HMGB1.
5e8,20,21 Therefore,
HMGB1 release through tumor cell death might have effect
on both the local inflammatory responses at the tumor site
and the development of tumor.
Statistical analysis showed that serum HMGB1 levels were
significantly positive correlated with tumor size and tumor
stage. These findings may suggest the strong associations of
HMGB1 with lung cancer progression. Overexpression of
HMGB1 can contribute to tumorgenesis and tumor metastasis
by altering gene expression with cells, and these genes were
reported to play key roles in different biological processes of
neoplasm progression and metastasis including cell cycle and
growth regulators (e.g., cdc25A), oncogenes and tumor
suppressor genes (e.g., met), DNA damage response, repair
and recombination genes (e.g., DNase X), cell adhesion,
mobility, and invasion genes (e.g., MMPs), angiogenesis
regulators (e.g, FGFR2), and cell-cell interaction genes (e.g.,
cadherin 12).6 Extracellular HMGB1 transduse cellular signals
by interacting with at least three receptors: RAGE, TLR2 and
TLR4. Signalling through RAGE leads to activation of the
nuclear factor-kB (NF-kB)pathway,mitogen activatedprotein
kinase (MAPK), type IV collagenase (MMP-2/-9), which are
important for cancer cell growth, invasion, and metas-
tasis.4,5,13,22 The suppression of tumor growth and metastasis
by blocking RAGE-HMGB1 complex in mice had been reporte-
d.13Overexpression of HMGB1 and RAGE has been strongly
associated with atypical and increased size of colorectal
adenomas, colorectal metastases to lymph nodes and distal
organs, andpoor prognosis at any colorectal cancer stage.17 In
conclusion, HMGB1 could be a useful and specific marker for
evaluating lung cancer (NSCLC) progression, and further
studies should clarify its clinical validity and prognostic
implications.
Conflict of interest
None declared.
Reference
1. Bustin M, Lehn DA, Landsman D. Structural features of the HMG
chromosomal proteins and their genes. Biochim Biophys Acta
1990;1049:231e43.
2. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as
a DNA-binding cytokine. J Leukoc Biol 2002;72:1084e91.
3. Calogero S, Grassi F, Aguzzi A, Voigtla¨nder T, Ferrier P,
Ferrari S, et al. The lack of chromosomal protein Hmg1 does
not disrupt cell growth but causes lethal hypoglycaemia in
newborn mice. Nat Genet 1999;22:276e80.
4. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-
Querini P. HMGB1: guiding immunity from within. Trends
Immunol 2005;26:381e7.5. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in
inflammation and sepsis. J Intern Med 2004;255:320e31.
6. Evans A, Lennard TW, Davies BR. High-mobility group protein
1(Y): metastasis-associated or metastasis-inducing? J Surg
Oncol 2004;88:86e99.
7. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R,
Colombetti S, Mondino A, et al. Extracellular HMGB1, a signal
of tissue damage, induces mesoangioblast migration and
proliferation. J Cell Biol 2004;164:441e9.
8. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein
HMGB1 by necrotic cells triggers inflammation. Nature 2002;
418:191e5.
9. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B,
Catalanotti F, Giazzon M, et al. HMGB1 is an endogenous
immune adjuvant released by necrotic cells. EMBO Rep 2004;5:
825e30.
10. Zeh 3rd HJ, Lotze MT. Addicted to death: invasive cancer and
the immune response to unscheduled cell death. J Immunother
2005;28:1e9.
11. Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H,
Kalinski P, et al. Cytolytic cells induce HMGB1 release from
melanoma cell lines. J Leukoc Biol 2007;81:75e83.
12. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced gly-
cation end products (RAGE)-mediated neurite outgrowth and
activation of NF-kappaB require the cytoplasmic domain of the
receptor but different downstream signaling pathways. J Biol
Chem 1999;274:19919e24.
13. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al.
Blockade of RAGE-amphoterin signalling suppresses tumour
growth and metastases. Nature 2000;405:354e60.
14. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY,
Strassheim D, et al. High mobility group box 1 protein interacts
with multiple Toll-like receptors. Am J Physiol Cell Physiol
2006;290:C917e24.
15. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E.
Immune activation and chronic inflammation as the cause of
malignancy in oral lichen planus: is there any evidence? Oral
Oncol 2004;40:120e30.
16. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The
receptor for advanced glycation end products (RAGE) is
a cellular binding site for amphoterin. Mediation of neurite
outgrowth and co-expression of rage and amphoterin in the
developing nervous system. J Biol Chem 1995, 27;270:
25752e61.
17. Sasahira T, Akama Y, Fujii K, Kuniyasu H. Expression of
receptor for advanced glycation end products and
HMGB1/amphoterin in colorectal adenomas. Virchows Arch
2005;446:411e5.
18. Mountain CF. Revisions in the international system for staging
lung cancer. Chest 1997;111:1710e7.
19. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M,
Che J, et al. HMG-1 as a late mediator of endotoxin lethality in
mice. Science 1999;285:248e51.
20. Lim SC, Choi JE, Kim CH, Duong HQ, Jeong GA, Kang HS, et al.
Ethyl pyruvate induces necrosis-to-apoptosis switch and
inhibits high mobility group box protein 1 release in A549 lung
adenocarcinoma cells. Int J Mol Med 2007;20:187e92.
21. Carmeliet P. Angiogenesis in life, disease and medicine. Nature
2005;438:932e6.
22. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y. Expression of
receptor for advanced glycation end products (RAGE) and MMP-
9 in human pancreatic cancer cells. Hepatogastroenterology
2004;51:928e30.
